A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.
In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 +/- 26 x 10(6) IU m-2] and C1 esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 +/- 12 x 10(6) IU m-2) or escalating-dose (CD 99 +/- 8 x 10(6) IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + C1-INH (C3a = 10.5 +/- 3.2 nmol l-1) than following standard (14.1 +/- 8.4 nmol l-1) or escalating-dose (18.3 +/- 2.9 nmol l-1) IL-2. This study demonstrates that C1-INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.
Ogilvie
A C
AC
Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
Baars
J W
JW
Eerenberg
A J
AJ
Hack
C E
CE
Pinedo
H M
HM
Thijs
L G
LG
Wagstaff
J
J
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D003174:Complement C1 Inactivator Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D015926:Complement C3a / Q000378:metabolism; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000633:toxicity*; D007680:Kidney Neoplasms / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D008875:Middle Aged; D010865:Pilot Projects
D003174:Complement C1 Inactivator Proteins; D007376:Interleukin-2; D015926:Complement C3a